Enjoy complimentary customisation on priority with our Enterprise License!
The global epigenetics market size is estimated to grow by USD 1,477.78 million at a CAGR of 14.75% between 2023 and 2028.
Epigenetics involving heritable gene expression changes without altering DNA sequences, is gaining interest in non-oncological diseases. Environmental factors trigger these changes, impacting conditions like cardiovascular disease, diabetes, neurodegenerative, and psychiatric disorders. Studies show epigenetic involvement in atherosclerosis, insulin resistance, and Alzheimer's. Recognizing its diagnostic role has led to the development of therapies targeting key enzymes like histone deacetylases and DNA methyltransferases, with approved applications for non-oncological diseases and ongoing investigations for potential therapeutic use. Hence, such factors are expected to drive market growth during the forecast period.
The market research and growth report also includes an in-depth analysis of drivers, trends, and challenges. Our market analysis and report examine historical data from 2018-2022, besides analyzing the current market scenario.
To learn more about this report, Download Report Sample
The market share growth by the oncology segment will be significant during the forecast period. The adoption of this in the oncology segment is significant due to the increasing prevalence of cancers globally. Cancer can be caused by a variety of factors, including genetics, lifestyle choices, and exposure to certain environmental factors. However, one of the most important factors in the development of cancer is epigenetics.
Get a glance at the market contribution of various segments Download PDF Sample
The oncology segment was valued at USD 504.06 million in 2018. Some cancers are caused by changes in gene expression that are passed down from parents to children. Other cancers develop over time as a result of exposure to certain lifestyle factors or environmental toxins. Furthermore, many researchers are working to identify and categorize epigenetic patterns linked to cancer, but the process is slowed by the fact that each identified change must be confirmed in many patients. Due to such factors, the demand for these solutions is expected to rise in the oncology segment. Hence, the above-mentioned factors are expected to drive the growth of the oncology segment in the global market during the forecast period.
Reagents are substances that can be used to produce a desired reaction, often in the context of chemical or biological research. In this field, reagents are commonly used to alter the epigenetic state of cells, which can influence gene expression. Additionally, epigenetic modifications play an important role in regulating gene expression, and thus, the use of reagents to alter these modifications can be a powerful tool for researchers studying this process. Thus, due to the above-mentioned factors, demand for reagents is expected to increase, which is expected to fuel the growth of the market via the reagents segment during the forecast period.
Kits are mostly used for checking the changes in the way genes are expressed in human beings. Primarily kits are used to screen for genetic disorders and predict how a person will respond to certain medications. Furthermore, the need for epigenetic kits is driven by several factors, including an increase in the prevalence of chronic illnesses, an aging population, and the use of epigenetic treatments. Furthermore, the increasing number of vendors engaged in the creation of advanced kits and the general increase in public awareness will drive the growth of the kits segment of the market during the forecast period.
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 39% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The North American market is on the rise due to increased adoption driven by rising chronic diseases, growing healthcare spending, and the concentration of key market players in the region. The presence of leading biotech and life sciences companies, coupled with the export of these instruments to other regions, fuels global service delivery.
Additionally, the significant number of clinical trials in North America, particularly in the US, further boosts the demand in drug development. The high incidence of cancer in the region amplifies the need for this in cancer research and diagnostics, offering promising growth opportunities. Increased funding for cancer genomics in the US will further drive the adoption of these in research. Hence, such factors are expected to drive market growth in the North America region during the forecast period.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
Abcam plc: The company offers research which provides studies focused on changes in DNA that do not involve alterations to the underlying sequence rather than changes in organisms.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges.
Rising strategic collaboration among companies is the key factor driving market growth. Several major market players are embarking on a variety of strategic efforts, such as partnerships and new product development, which is expected to become a prominent trend in the market. Several firms are collaborating to develop these solutions to extend their product line and operations globally.
For instance, in September 2021, Active Motif Inc. (Active Motif) announced a partnership with Proteintech Group (Proteintech) to focus on bringing into the translational and precision medicine segments. Hence, such factors are expected to fuel the growth of the market during the forecast period.
The increasing number of recent developments is the primary trend shaping market growth. The market is witnessing an increasing number of new product launches. The new product additions will motivate more consumers to purchase a variety according to their requirements. The increasing number of new product launches also increases the competition in the market, which, in turn, will lead to innovation and differentiation. Align with market trends and analysis, because new product launches persuade consumers to try various products, manufacturers also focus on new product developments.
For instance, in April 2021, Eurofins Scientific SE announced the launch of its new SARS-CoV-2 Full-length Genome Sequencing service, which is a new NGS service that allows for end-to-end monitoring of the coronavirus genome sequence and mutational drift. Thus, such factors are expected to drive the growth of the market during the forecast period.
Privacy issues concerning data leakage of genetic information is a major challenge that affects market growth. The genetic information of an individual is highly confidential. The technological advances that are enabling researchers to easily sequence and interpret genomic information required for research and clinical uses have increased the risk of data privacy of an individual's genetic information. As genetic information is stored in cloud databases for easy access to doctors and insurance companies, there is an increased privacy concern related to its use globally.
Additionally, the blood and tissue samples collected in medical settings during biopsies can serve as sources of samples for genetic analysis, which increases the chances of data leakage. Furthermore, the use of genomic testing for routine procedures in clinical settings increases the threat to patient privacy, as patients are potentially vulnerable to the misuse of their genetic information. Thus, the lack of high-end technology to store genetic information confidentially is likely to impede market growth during the forecast period.
The market growth analysis report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Customer Landscape
The market report forecasts market growth and forecasting by revenue at global, regional & country levels and provides an analysis of the latest market growth and trends opportunities from 2018 to 2028.
The market is witnessing significant growth driven by the rising prevalence of non-oncology conditions such as cardiovascular disorders (CVDs), reproductive problems, autoimmune diseases, and cognitive function disorders. External stimuli and causative agents like heavy metals, pesticides, cigarette smoke, hormones, radiation, and viruses contribute to epigenetic changes, necessitating advanced testing and assays.
Epigenetic testing and assays play a crucial role in identifying epigenetic modifications, including DNA methylation, RNA regulation, histone modification, and control of genes. Research and development efforts focus on understanding epigenetic pathways and their role in various ailments, including lung cancer, breast cancer, cervical cancer, liver cancer, and oral cavity cancer. Healthcare R&D spending, government support, and advancements in epigenetic products drive innovation in the field. They offers insights into essential nutrients and monocytes through peripheral blood samples. As the market expands, the integration of epigenetic processes into drug discovery and development holds promise for addressing complex healthcare challenges beyond oncology conditions, enhancing affordability, and improving patient outcomes.
Epigenetics Market Scope |
|
Report Coverage |
Details |
Page number |
163 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 14.75% |
Market Growth 2024-2028 |
USD 1,477.78 million |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
13.54 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 39% |
Key countries |
US, Canada, Germany, UK, and China |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Abcam plc, Active Motif Inc., Agilent Technologies Inc., Bio Rad Laboratories Inc., Bio Techne Corp., Eisai Co. Ltd., Element Biosciences Inc, EpiGentek Group Inc., Eurofins Scientific SE, F. Hoffmann La Roche Ltd., Illumina Inc., Merck KGaA, New England Biolabs Inc., Novartis AG, Pacific Biosciences of California Inc., PerkinElmer Inc, Promega Corp., QIAGEN NV, Thermo Fisher Scientific Inc., Zymo Research Corp., and CellCentric Ltd. |
Market dynamics |
Parent market analysis, Market forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download the Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.